BnR Summit 2026

Belt & Road Summit - Deal-Making 2026

9 – 15 Sept 2026 | Hong Kong, China (Hong Kong)

Register
Register
Register

Shanghai Haiju Biotechnology Co., Ltd.

About

New Antitumor Drug Project ( HJ550 ):

the first bivalent platinum drug targeting the tumor microenvironment, redefine the first-line treatment paradigm for cancer.

Technology

Bio-TechHealth Technology

Additional Information

Other Place of Business

North AmericaHong KongMainland China

Terms and Conditions & Disclaimer

I agree

Representatives

CEO

Shanghai Haiju Biotechnology Co., Ltd.

Marketplace (2)

  • Project

    Novel Platinum-Based Drug (HJ-550 )

    HJ-550 may redefine the sequence of first-line cancer therapies and mark a milestone in the history of oncology treatment.

    • Yes
    • Yes
    • Debt
    • Equity
    • Bio-Tech
    • Technology
    • Joint Venture
    • Private Project
    • Convertible Loan
    • Equity (private)
    • Financial Services
    • Investment Banking
    • Professional Services
    • Mergers & Acquisition
    • 500,001 to 1,000,000 USD
    • Direct Equity Investment
    • Institutional Investment
    • 10,000,001 to 25,000,000 USD
    • Private Equity & Venture Capital
    • Investment / Financing Discussion
    Author

    CEO at Shanghai Haiju Biotechnology Co., Ltd.

    China

  • Project

    Novel MET Amplification-Targeting Small-Molecule Kinase Inhibitor (HJ-462 BIC)

    protein kinase inhibitors with ingenious molecular designs

    • Yes
    • Yes
    • Debt
    • Equity
    • Bio-Tech
    • Technology
    • Joint Venture
    • Private Project
    • Health Technology
    • Convertible Loan
    • Equity (private)
    • Financial Services
    • Direct Equity Investment
    • 5,000,001 to 7,500,000 USD
    • 1,000,001 to 2,500,000 USD
    • Investment / Financing Discussion
    • M&A / Strategic Acquisition Opportunity
    Author

    CEO at Shanghai Haiju Biotechnology Co., Ltd.

    China